Evidence map›Paper›PMID 32002722›Full record

ArticleFamilial cancer2020

Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway.

Eli Marie Grindedal, Kjersti Jørgensen, Pernilla Olsson, Berit Gravdehaug, Hilde Lurås, Ellen Schlichting, Tone Vamre, Teresia Wangensteen, Cecilie Heramb, Lovise Mæhle

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Familial cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eli Marie GrindedalDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway. eligr@ous-hf.no.ORCID 0000-0002-8198-1706
Kjersti JørgensenDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Pernilla OlssonDepartment of Surgery, Section of Breast and Endocrine Surgery, Innlandet Hospital, Hamar, Norway.
Berit GravdehaugDepartment of Breast and Endocrine Surgery, Akershus University Hospital, Lørenskog, Norway.
Hilde LuråsHealth Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
Ellen SchlichtingInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Tone VamreDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Teresia WangensteenDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Cecilie HerambDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Lovise MæhleDepartment of Medical Genetics, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies have shown that a significant number of eligible breast cancer patients are not offered genetic testing or referral to genetic counseling. To increase access to genetic testing in South Eastern Norway, testing has since 2014 been offered directly to breast cancer patients by surgeons and oncologists. This practice is termed "mainstreamed genetic testing". The aim of this study was to investigate to what extent patients in South Eastern Norway are offered testing. Three hundred and sixty one patients diagnosed in 2016 and 2017 at one regional and one university hospital in South Eastern Norway were included. Data on whether the patients fulfilled the criteria, whether they had been offered testing and if they were tested were collected. In total, 26.6% (96/361) fulfilled the criteria for testing. Seventy five percent (69/92) of these were offered testing, and 71.7% (66/92) were tested. At the university hospital, 90.2% (37/41) of eligible patients were offered testing, and at the regional hospital 62.7% (32/51). Fifty two percent (12/23) of eligible patient not offered testing were younger than 50 years at time of diagnosis. As many as 95.4% (125/131) of all patients who were offered testing, wanted to be tested. The majority of patients who fulfilled the criteria were offered testing, supporting the practice of mainstreamed genetic testing. There were nevertheless differences in rates of testing between the hospitals that affected all groups of patients, indicating that genetic testing may not be equally accessible to all patients. We suggest that efforts should be made to increase awareness and improve routines for genetic testing of breast cancer patients in Norway.

Indexed as

Genes, BRCA1AdultAgedAged, 80 and overAge FactorsBreast NeoplasmsBreast Neoplasms, MaleFemaleGenetic TestingHealth Care SurveysHospitalsHumansMaleMiddle AgedNeoplastic Syndromes, HereditaryNorwayBRCABreast cancerGenetic testingMainstreaming cancer genetics

Identifiers

PMID32002722
PMCPMC7101297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.